MedTrace Logo

Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis

NCT04705870 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-01-05

No results posted yet for this study

Summary

Patients who have agreed to participate in the study will complete the MRI protocol as part of routine care, to which four additional 20-minute sequences will be added.

MRI of routine care in the context of MS includes at least the following sequences:

* 3D T1 TFE (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR (3 minutes)
* SWI EPI 0.6 iso (7 minutes)

The sequences added by the search are:

* SWI non EPI QSM 6 echo (10 minutes)
* SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)
* SWI EPI to TR equivalent to SWI non EPI (6 minutes)

These sequences will be acquired before or after the injection of gadolinium (if present in the examination of routine care). For examinations carried out with injection, the order of carrying out the 4 post-injection SWI sequences will be random.

Conditions

Interventions

DEVICE

cerebral MRI

MRI of routine care in the context of MS includes at least the following sequences: * 3D T1 TFE (2 minutes) * T2 TSE (2 minutes) * 3D FLAIR (3 minutes) * SWI EPI 0.6 iso (7 minutes) The sequences added by the search are: * SWI non EPI QSM 6 echo (10 minutes) * SWI EPI in resolution equivalent to non-EPI SWI (3 minutes) * SWI EPI to TR equivalent to SWI non EPI (6 minutes)

Sponsors & Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-02
Primary Completion
2023-05-24
Completion
2023-05-24

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04705870 on ClinicalTrials.gov